Iterum Therapeutics plc
ITRM
$0.42
$0.000.77%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.76% | 15.04% | 36.59% | 35.44% | 1.75% |
| Total Depreciation and Amortization | 184.23% | 8.75% | -52.61% | -83.77% | -73.53% |
| Total Amortization of Deferred Charges | -128.25% | -41.94% | -17.90% | -2.18% | 82.50% |
| Total Other Non-Cash Items | 150.66% | 197.10% | 198.85% | 204.51% | 136.43% |
| Change in Net Operating Assets | 79.07% | 74.60% | -130.29% | -560.77% | -283.59% |
| Cash from Operations | 44.81% | 64.87% | 60.89% | 31.93% | -14.97% |
| Capital Expenditure | -600.00% | -300.00% | 69.23% | 84.62% | 96.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -96.41% | -73.11% | -56.79% | -22.01% | 114.98% |
| Cash from Investing | -96.45% | -73.12% | -56.78% | -21.97% | 115.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 129.69% | 285.62% | 222.24% | 2,481.33% | 1,426.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 19.68% | 100.91% | 38.30% | 2,481.33% | 1,426.54% |
| Foreign Exchange rate Adjustments | 74.71% | 41.46% | 6.58% | -22.95% | -335.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -128.04% | 191.92% | 155.74% | 220.19% | 154.70% |